ReviewNature reviews. Rheumatology2010
Immunotherapy of myositis: issues, concerns and future prospects.
Review in Nature reviews. Rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.
- Physical therapy in adult inflammatory myopathy patients: a systematic review.Clinical rheumatology · 2019Pooled it
- Mutual reinforcement of lymphotoxin-driven myositis and impaired autophagy in murine muscle.Brain : a journal of neurology · 2025Article
- Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases.Immunity, inflammation and disease · 2025Review
- Modulation of mitochondrial activity by sugarcane (Saccharum officinarum L.) top extract and its bioactive polyphenols: a comprehensive transcriptomics analysis in C2C12 myotubes and HepG2 hepatocytes.Natural products and bioprospecting · 2024Article
- Dermatomyositis with Eosinophils.Dermatopathology (Basel, Switzerland) · 2023Article
- Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility.Journal of interventional medicine · 2023Article
- Muscle glycome in idiopathic inflammatory myopathies: Impact in IL-6 production and disease prognosis.iScience · 2023Article
- Management of dermatomyositis patients amidst the COVID-19 pandemic: Two case reports.Medicine · 2022Article
- Iron controls T helper cell pathogenicity by promoting glucose metabolism in autoimmune myopathy.Clinical and translational medicine · 2022Article
- Identification of hub biomarkers and immune cell infiltration characteristics of polymyositis by bioinformatics analysis.Frontiers in immunology · 2022Article
- The Immunomodulatory Function of Vitamin D, with Particular Reference to SARS-CoV-2.Medicina (Kaunas, Lithuania) · 2021Review
- Review
- Treatment of Active Idiopathic Inflammatory Myopathies by Low-Dose Interleukin-2: A Prospective Cohort Pilot Study.Rheumatology and therapy · 2021Article
- Role of Immunoglobulins in Muscular Dystrophies and Inflammatory Myopathies.Frontiers in immunology · 2021Review
- Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series.Therapeutic advances in neurological disorders · 2021Review
- Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2020Review
- Supervised Physical Therapy and Polymyositis/Dermatomyositis-A Systematic Review of the Literature.Neurology international · 2020Review
- Reduced miR-146a Promotes REG3A Expression and Macrophage Migration in Polymyositis and Dermatomyositis.Frontiers in immunology · 2020Article
- Polymyositis and dermatomyositis - challenges in diagnosis and management.Journal of translational autoimmunity · 2019Article
- Interleukin-37 (IL-37) Suppresses Pertussis Toxin-Induced Inflammatory Myopathy in a Rat Model.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main inflammatory myopathies within the myositis group include polymyositis, dermatomyositis and inclusion-body myositis (IBM). Although potentially treatable, various practical issues have an impact on the response of these conditions to therapy. The most common reason for therapeutic failure is that the treatment targets the wrong disease, often owing to poor distinction of polymyositis from difficult-to-treat mimics such as sporadic IBM, necrotizing myopathies and inflammatory dystrophies. Evidence from uncontrolled studies suggests that polymyositis and dermatomyositis respond to treatment with prednisone at least to some degree. Empirically, adding an immunosuppressive drug might offer a 'steroid-sparing' effect or perhaps additional benefit. Intravenous immunoglobulin is proven effective as a second-line agent in patients with dermatomyositis and also seems to be effective for those with polymyositis, but offers only minimal and transient benefit to a small proportion of patients with IBM. Small, uncontrolled series suggest other agents such as rituximab or tacrolimus might offer some benefit in disease refractory to the aforementioned therapies, although IBM is resistant to most therapies. Novel agents are emerging as potential treatment options for all forms of myositis. This Review highlights common pitfalls in therapy, discusses emerging new therapies, and provides a practical therapeutic algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.